Hair loss concerns and treatments like Minoxidil and Finasteride are humorously discussed. The community's quirks and dedication to battling hair loss are highlighted.
The user is using a combination of finasteride, dutasteride, oral and topical minoxidil, PRP, and stem cell treatments for hair loss. They report slowed shedding and new vellus hairs on the hairline, questioning if they are a strong responder to the treatment.
The user experienced increased hair shedding after switching to a new treatment with higher doses of finasteride (0.3%), minoxidil (7%), ketoconazole (2.2%), and biotin (0.2%). They are curious about the shedding but not concerned about noticeable thinning.
The user switched from topical to oral finasteride and minoxidil, noticing thicker and longer baby hairs, suggesting potential regrowth at the temples. Other users agree it looks like a sign of success.
The user experienced significant hair regrowth using finasteride and minoxidil. They plan to switch to dutasteride for its potency after confirming their body's tolerance to DHT blockers.
Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.
PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
The conversation humorously discusses the effects of finasteride on sexual orientation and hair improvement, with users joking about its potential to change attraction. It also mentions other treatments like dutasteride and minoxidil, with some users sharing their experiences and side effects.
Blocking DHT may slow down aging and improve skin, with users reporting positive effects from finasteride. Minoxidil and RU58841 are also mentioned as treatments.
The user is experiencing increased hair shedding after 7 months of using a topical solution and is considering switching to oral treatment. They are concerned about thinning hair around the corners and temples.
Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.
A user on finasteride for 7+ months shared bloodwork results, questioning if high DHT levels and testosterone could affect cholesterol. Replies suggest consulting a doctor and question the high testosterone levels.
The conversation discusses preventing hair loss during detransitioning, with suggestions to use finasteride or dutasteride as DHT blockers. The user is also considering rosemary oil and monitoring testosterone levels.
The user is considering switching from Minoxidil to dutasteride for hair loss treatment but is concerned about the potential for increased shedding. They are seeking advice on whether to wait for the current shedding phase to subside before starting dutasteride.
A woman with AGA is using spironolactone, dutasteride, finasteride, oral minoxidil, bicalutamide, and anti-androgenic birth control but still experiences worsening hair loss. Steroid shots temporarily stop her hair shedding, leading her to question her biopsy results.
Beta-sitosterol may inhibit 5-alpha reductase type 2 enzyme, potentially reducing DHT levels and promoting hair growth, similar to finasteride but possibly with fewer side effects. Its effectiveness and side effects compared to other treatments like saw palmetto and finasteride remain uncertain due to limited research.
PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.
Reducing sugar intake may lessen scalp itchiness associated with hair loss, even when using treatments like finasteride. Some users also report similar symptoms while on dutasteride.
The user is experiencing prolonged hair shedding despite using 1mg finasteride, 2.5mg minoxidil, and considering adding topical finasteride. They are also deficient in Vitamin D and B, and are exploring if supplements or dosage adjustments could help.
A 27-year-old Asian male is treating hair loss with 1mg oral finasteride, topical minoxidil twice daily, and 1.5mm microneedling weekly. The discussion is about his progress with these treatments.
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.
Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.
The user has been using a hair solution with 0.3% finasteride and 5% minoxidil, along with microneedling, but is experiencing more thinning on one side. Suggestions include checking application techniques and ensuring microneedling is not overdone.
High frequency ultrasonography and HR-MRI can help identify hair shedding causes like inflammation and fibrosis. The conversation discusses the potential of using these technologies to evaluate treatments like Verteporfin for hair regeneration.
The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.
The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.
The user experienced hair regrowth with Minoxidil but noticed some hair loss after stopping microneedling for two months. They are hesitant to use finasteride again due to side effects and are considering other DHT blockers.